Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Rhabdoid Tumor 1 Pancreatic Adenocarcinoma 1 Neoplasms 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Chordoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced Liver Cancers 1

Interventions

pembrolizumab 16 Carboplatin 10 Paclitaxel 8 Nivolumab 7 Bevacizumab 6 Gemcitabine 4 Fulvestrant 4 Cisplatin 4 olaparib 3 lenvatinib 3 abemaciclib 3 PM 01183 3 Oxaliplatin 3 Leucovorin 3 Letrozole 3 Docetaxel 3 AZD5305 3 tisotumab vedotin 2 spartalizumab 2 sarilumab 2 sargramostim 2 sacituzumab govitecan 2 ribociclib 2 palbociclib 2 epacadostat 2 enzalutamide 2 dostarlimab 2 cemiplimab 2 anlotinib 2 X-Rays 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Endometrial Neoplasms × Tiragolumab × Clear all

NCT04486352 2026-04-01

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡